SearcharxivSearch

arXiv subjects

Emily Alger

Publications and source records attributed to Emily Alger.

2 recordsLinked to original sources

FairBED: A Bayesian Experimental Design Approach to Gathering Fairer Data

Frameworks for ensuring fairness in machine learning typically focus on learning fair models from existing data. But this endeavor is often undermined by biases already present in that data. We therefore look to modify the data acquisition process itself to help gather fairer data that is inherently more suitable for training fair predictors. To this end, we introduce FairBED, which provides novel formulations for quantifying the fairness of datasets themselves based on the idea that fair datasets should be uninformative about sensitive attributes. We then use this to construct practical fairness-aware Bayesian experimental design (BED) objectives that maximize expected information gain about the target quantity of interest while minimizing expected information gain about sensitive attributes. We further derive a theoretical link between FairBED and demographic parity, and show empirically that models trained on data gathered using FairBED provide improved fairness-accuracy trade-offs compared to randomly acquired data and conventional BED.

stat.ML

The use of restricted mean survival time to estimate treatment effect under model misspecification, a simulation study

The use of the non-parametric Restricted Mean Survival Time endpoint (RMST) has grown in popularity as trialists look to analyse time-to-event outcomes without the restrictions of the proportional hazards assumption. In this paper, we evaluate the power and type I error rate of the parametric and non-parametric RMST estimators when treatment effect is explained by multiple covariates, including an interaction term. Utilising the RMST estimator in this way allows the combined treatment effect to be summarised as a one-dimensional estimator, which is evaluated using a one-sided hypothesis Z-test. The estimators are either fully specified or misspecified, both in terms of unaccounted covariates or misspecified knot points (where trials exhibit crossing survival curves). A placebo-controlled trial of Gamma interferon is used as a motivating example to simulate associated survival times. When correctly specified, the parametric RMST estimator has the greatest power, regardless of the time of analysis. The misspecified RMST estimator generally performs similarly when covariates mirror those of the fitted case study dataset. However, as the magnitude of the unaccounted covariate increases, the associated power of the estimator decreases. In all cases, the non-parametric RMST estimator has the lowest power, and power remains very reliant on the time of analysis (with a later analysis time correlated with greater power).

stat.ME